Loading clinical trials...
Loading clinical trials...
A Phase 3, Randomized, Double-blind, Study Evaluating Efficacy and Safety of Riliprubart Versus Intravenous Immunoglobulin (IVIg) in Participants With Chronic Inflammatory Demyelinating Polyneuropathy
Conditions
Interventions
riliprubart
Placebo
+4 more
Locations
115
United States
Alabama Neurology Associates- Site Number : 8400019
Homewood, Alabama, United States
Honor Health Scottsdale Osborn Medical Center- Site Number : 8400014
Scottsdale, Arizona, United States
Keck School of Medicine of University of Southern California- Site Number : 8400002
Los Angeles, California, United States
University of California Irvine Medical Center- Site Number : 8400007
Orange, California, United States
Yale University School of Medicine- Site Number : 8400018
New Haven, Connecticut, United States
AdventHealth Orlando- Site Number : 8400006
Orlando, Florida, United States
Start Date
August 21, 2024
Primary Completion Date
July 9, 2027
Completion Date
January 12, 2029
Last Updated
April 21, 2026
NCT06858579
NCT06752356
NCT06920004
NCT07027111
NCT06637072
NCT07121985
Trial Transparency email recommended (Toll free for US & Canada)
CONTACT
800-633-1610contact-us@sanofi.comLead Sponsor
Sanofi
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions